New drug combo takes aim at Hard-to-Treat KRAS cancers
NCT ID NCT04973163
First seen Nov 01, 2025
Summary
This early-phase study tests a new drug, BI 1823911, alone or with another drug (BI 1701963), in people with advanced solid tumors that have a KRAS G12C mutation. The goal is to find a safe dose and see if the drugs can shrink tumors. About 30 adults with cancers like lung, colorectal, or pancreatic cancer who have run out of other options are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS, KRAS MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brussels - HOSP Jules Bordet
Anderlecht/Brussels-Capital, 1070, Belgium
-
Edegem - UNIV UZ Antwerpen
Edegem/Antwerpen, 2650, Belgium
-
Hospital Universitari Vall D Hebron
Barcelona, 08035, Spain
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021, United States
-
Sarah Cannon Research Institute at Mary Crowley
Dallas, Texas, 75230, United States
-
The Christie
Manchester, M20 4BX, United Kingdom
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UZ Leuven
Leuven/Vlaams-Brabant, 3000, Belgium
-
Universitair Ziekenhuis Gent
Gent/Oost-Vlaanderen, 9000, Belgium
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 1823911 (a KRAS inhibitor) and BI 1701963 (another KRAS-targeting drug)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced cancers that have a specific KRAS mutation.
What could go wrong
This is a very early (Phase 1) trial with only 30 participants, so safety and effectiveness are not yet known. The drugs may not shrink tumors or could cause side effects.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.